Vitamin D and Multiple Sclerosis

Abstract Recently, it has been clearly demonstrated that exogenous 1,25-dihydroxyvitamin D3, the hormonal form of vitamin D3, can completely prevent experimental autoimmune encephalomyelitis (EAE), a widely accepted mouse model of human multiple sclerosis (MS). This finding has focused attention on the possible relationship of this disease to vitamin D. Although genetic traits certainly contribute to MS susceptibility, an environmental factor is also clearly involved. It is our hypothesis that one crucial environmental factor is the degree of sunlight exposure catalyzing the production of vitamin D3 in skin, and, further, that the hormonal form of vitamin D3 is a selective immune system regulator inhibiting this autoimmune disease. Thus, under low-sunlight conditions, insufficient vitamin D3 is produced, limiting production of 1,25-dihydroxyvitamin D3, providing a risk for MS. Although the evidence that vitamin D3 is a protective environmental factor against MS is circumstantial, it is compelling. This theory can explain the striking geographic distribution of MS, which is nearly zero in equatorial regions and increases dramatically with latitude in both hemispheres. It can also explain two peculiar geographic anomalies, one in Switzerland with high MS rates at low altitudes and low MS rates at high altitudes, and one in Norway with a high MS prevalence inland and a lower MS prevalence along the coast. Ultraviolet (UV) light intensity is higher at high altitudes, resulting in a greater vitamin D3 synthetic rate, thereby accounting for low MS rates at higher altitudes. On the Norwegian coast, fish is consumed at high rates and fish oils are rich in vitamin D3. Further, experimental work on EAE provides strong support for the importance of vitamin D3 in reducing the risk and susceptibility for MS. If this hypothesis is correct, then 1,25-dihydroxyvitamin D3 or its analogs may have great therapeutic potential in patients with MS. More importantly, current research together with data from migration studies opens the possibility that MS may be preventable in genetically susceptible individuals with early intervention strategies that provide adequate levels of hormonally active 1,25-dihydroxyvitamin D3 or its analogs.

[1]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[2]  M. Holick Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. , 1987, Federation proceedings.

[3]  H. DeLuca,et al.  The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats. , 1972, Endocrinology.

[4]  R. Loewenson,et al.  The geographic distribution of multiple sclerosis: An examination of mathematical models☆ , 1973 .

[5]  J. Wolinsky,et al.  Measles encephalomyelitis--clinical and immunologic studies. , 1984, The New England journal of medicine.

[6]  W. Sibley,et al.  CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.

[7]  M. Holick,et al.  Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. , 1981, Science.

[8]  G. Schwartz Multiple sclerosis and prostate cancer: what do their similar geographies suggest? , 1992, Neuroepidemiology.

[9]  H. Panitch Influence of infection on exacerbations of multiple sclerosis , 2004, Annals of neurology.

[10]  J. Bollerslev,et al.  Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. , 1991, International journal of immunopharmacology.

[11]  B. Weinshenker,et al.  Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.

[12]  D. Bates,et al.  A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[13]  G. Ulett Geographic distribution of multiple sclerosis. , 1948, Diseases of the nervous system.

[14]  J. Lemire Immunomodulatory role of 1,25‐dihydroxyvitamin D3 , 1992, Journal of cellular biochemistry.

[15]  K. Westlund DISTRIBUTION AND MORTALITY TIME TREND OF MULTIPLE SCLEROSIS AND SOME OTHER DISEASES IN NORWAY , 1970, Acta neurologica Scandinavica.

[16]  R. Swanborg,et al.  Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis. , 1975, Journal of immunology.

[17]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[18]  R. Zinkernagel,et al.  The discovery of MHC restriction. , 1997, Immunology today.

[19]  H. Weiner,et al.  Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. , 1984, Journal of immunology.

[20]  J. Kurtzke,et al.  A method for estimating the age at immigration of white immigrants to South Africa, with an example of its importance. , 1970, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[21]  H. Rieder,et al.  The seasonal incidence of multiple sclerosis in Switzerland. , 1970, European neurology.

[22]  D. Katz,et al.  Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. , 1987, Immunology.

[23]  G. Schwartz Hypothesis: calcitriol mediates pregnancy's protective effect on multiple sclerosis. , 1993, Archives of neurology.

[24]  P. Goldberg Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .

[25]  M. Brentani,et al.  Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  C. Davenport MULTIPLE SCLEROSIS: FROM THE STANDPCINT OF GEOGRAPHIC DISTRIBUTION AND RACE , 1922 .

[27]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[28]  J. Strominger,et al.  Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases , 1995, The Journal of experimental medicine.

[29]  J. Herbert,et al.  High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis , 1994, Neurology.

[30]  A. Sadovnick,et al.  The role of genetic factors in multiple sclerosis susceptibility , 1994, Journal of Neuroimmunology.

[31]  P. Brachet,et al.  Synthesis of 1,25‐dihydroxyvitamin D3 by rat brain macrophages in vitro , 1994, Journal of neuroscience research.

[32]  J. Kurtzke ON THE FINE STRUCTURE OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS , 1967, Acta neurologica Scandinavica.

[33]  B. Trapp,et al.  Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis , 1996, Journal of Neuroimmunology.

[34]  E. Kabat,et al.  THE PATHOLOGY OF ACUTE DISSEMINATED ENCEPHALOMYELITIS PRODUCED EXPERIMENTALLY IN THE RHESUS MONKEY AND ITS RESEMBLANCE TO HUMAN DEMYELINATING DISEASE , 1947, Journal of neuropathology and experimental neurology.

[35]  J. Adams,et al.  INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.

[36]  P. Hjelmström,et al.  A Critical Role for Lymphotoxin in Experimental Allergic Encephalomyelitis , 1997, The Journal of experimental medicine.

[37]  J M Lemire,et al.  1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.

[38]  D. Hinds,et al.  A full genome search in multiple sclerosis , 1996, Nature Genetics.

[39]  R. Knobler,et al.  Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. , 1987, Clinical immunology and immunopathology.

[40]  P. Henkart,et al.  A protease-dependent TCR-induced death pathway in mature lymphocytes. , 1995, Journal of immunology.

[41]  H. DeLuca,et al.  Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Hutchinson,et al.  Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .

[43]  L. Weiner,et al.  Defective post–thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis , 1996, Nature Medicine.

[44]  H. DeLuca,et al.  5,6-Trans-25-Hydroxycholecalciferol: Vitamin D Analog Effective on Intestine of Anephric Rats , 1972, Science.

[45]  H. Newmark,et al.  Vitamin D adequacy: a possible relationship to breast cancer. , 1994, Advances in experimental medicine and biology.

[46]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Demignon,et al.  Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface. , 1991, Gynecologic and obstetric investigation.

[48]  C. C. Limburg The geographic distribution of multiple sclerosis and its estimated prevalence in the United States. , 1950, Research publications - Association for Research in Nervous and Mental Disease.

[49]  A. Meshorer,et al.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide , 1971, European journal of immunology.

[50]  S. Tonegawa,et al.  CD4+ T Cells Prevent Spontaneous Experimental Autoimmune Encephalomyelitis in Anti–Myelin Basic Protein T Cell Receptor Transgenic Mice , 1998, The Journal of experimental medicine.

[51]  P. Goodfellow,et al.  A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.

[52]  P. Malloy,et al.  The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  H. DeLuca,et al.  Effect of vitamin D deficiency on fertility and reproductive capacity in the female rat. , 1980, The Journal of nutrition.

[54]  M. Holick PHOTOBIOLOGY, METABOLISM, AND CLINICAL ASPECTS OF VITAMIN D , 1981 .

[55]  S. Manolagas,et al.  Interactions of 1,25-dihydroxyvitamin D3 and the immune system , 1985, Molecular and Cellular Endocrinology.

[56]  N. Roberts,et al.  Seasonal Variation in Serum 25-Hydroxy Vitamin D3 Does Not Affect 1,25-Dihydroxy Vitamin D , 1994, Annals of clinical biochemistry.

[57]  H. Deluca Vitamin D: 1993 , 1993 .

[58]  W. Stumpf,et al.  Vitamin D (soltriol), light, and reproduction. , 1989, American journal of obstetrics and gynecology.

[59]  H. DeLuca,et al.  1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .

[60]  S. Fey,et al.  MS and the group‐specific component , 1988, Acta neurologica Scandinavica.

[61]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[62]  Y. Taketani,et al.  A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  R. Swank,et al.  Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. , 1952, The New England journal of medicine.

[64]  S. Krane,et al.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.

[65]  J. Adams,et al.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. , 1983, The Journal of clinical investigation.

[66]  H. DeLuca Vitamin D: the vitamin and the hormone. , 1974, Federation proceedings.

[67]  H. DeLuca,et al.  Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. , 1979, The Journal of clinical investigation.

[68]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[69]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[70]  G. Dean,et al.  Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. , 1967, British medical journal.

[71]  J. Presthus REPORT ON THE MULTIPLE SCLEROSIS INVESTIGATIONS IN WEST‐NORWAY , 1960, Acta psychiatrica Scandinavica. Supplementum.

[72]  I. Weissman,et al.  Infection and multiple sclerosis: a possible role for superantigens? , 1994, Trends in microbiology.

[73]  H. DeLuca,et al.  Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter (*) , 1995, The Journal of Biological Chemistry.

[74]  W. Karpus,et al.  CD4+ suppressor cells differentially affect the production of IFN-gamma by effector cells of experimental autoimmune encephalomyelitis. , 1989, Journal of immunology.

[75]  H. DeLuca,et al.  1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. , 1998, Journal of immunology.

[76]  J. Lafaille,et al.  Regulatory Cd4 Ϩ T Cells Expressing Endogenous T Cell Receptor Chains Protect Myelin Basic Protein–specific Transgenic Mice from Spontaneous Autoimmune Encephalomyelitis , 1998 .

[77]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[78]  H. DeLuca The vitamin D story: a collaborative effort of basic science and clinical medicine 1 , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  G. Beebe,et al.  Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. , 1983, Journal of chronic diseases.

[80]  H. DeLuca,et al.  Molecular biology of vitamin D action. , 1994, Vitamins and hormones.

[81]  P. Goldberg,et al.  Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. , 1986, Medical hypotheses.

[82]  H. Link,et al.  Distribution of group‐specific component subtypes in multiple sclerosis , 1988, Acta Neurologica Scandinavica.

[83]  P. Brachet,et al.  1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.

[84]  J. Pike,et al.  Vitamin D3 receptors: structure and function in transcription. , 1991, Annual review of nutrition.

[85]  J. Zerwekh,et al.  Pathogenetic Role of lα,25-Dihydroxyvitamin D inarcoidosis and Absorptive Hypercalciuria: DifferentResponse to Prednisolone Therapy* , 1980 .

[86]  G. Harrell,et al.  BLOOD CHEMICAL CHANGES IN BOECK'S SARCOID WITH PARTICULAR REFERENCE TO PROTEIN, CALCIUM AND PHOSPHATASE VALUES. , 1939, The Journal of clinical investigation.

[87]  S. Epstein,et al.  Evidence for alteration of the vitamin D-endocrine system in blacks. , 1985, The Journal of clinical investigation.

[88]  E. Shevach,et al.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.

[89]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. , 1984, Science.

[90]  R. Bouillon,et al.  Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH)2D3 , 1995, Journal of Neuroimmunology.

[91]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[92]  H. Weiner,et al.  IL-10 is critical in the regulation of automimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice , 1998, Journal of Neuroimmunology.

[93]  M. Holick,et al.  The cutaneous photosynthesis of previtamin D3: a unique photoendocrine system. , 1981, The Journal of investigative dermatology.

[94]  J. Herbert,et al.  High‐dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  A. Sadovnick,et al.  The geographic distribution of multiple sclerosis: a review. , 1993, Neuroepidemiology.

[96]  N. Bell Bone and mineral metabolism in African Americans , 1997, Trends in Endocrinology & Metabolism.

[97]  C. Kovacs,et al.  Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. , 1997, Endocrine reviews.

[98]  S. Manolagas,et al.  1α,25-Dihydroxyvitamin D3 Receptor Distribution and Effects in Subpopulations of Normal Human T Lymphocytes* , 1989 .

[99]  T. Markestad,et al.  Effect of estrogen on vitamin D metabolism in tall girls. , 1983, The Journal of clinical endocrinology and metabolism.

[100]  P. Goldberg Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors , 1974 .

[101]  J. Kurtzke Epidemiologic evidence for multiple sclerosis as an infection , 1993, Clinical Microbiology Reviews.

[102]  E. Acheson,et al.  SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.

[103]  J. Adams,et al.  Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis , 1985, The Journal of experimental medicine.

[104]  H. DeLuca,et al.  Vitamin D: recent advances. , 1983, Annual review of biochemistry.

[105]  M. Holick 1,25-Dihydroxyvitamin D3 and the Skin: A Unique Application for the Treatment of Psoriasis , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[106]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[107]  T. Riise,et al.  Incidence of multiple sclerosis in Møre and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis. , 1996, Brain : a journal of neurology.

[108]  W. Sibley,et al.  Seasonal variation of multiple sclerosis exacerbations in Arizona , 1983, Neurology.

[109]  T. Clemens,et al.  1, 25-DIHYDROXYCHOLECALCIFEROL IN THE PATHOGENESIS OF THE HYPERCALCÆMIA OF SARCOIDOSIS , 1979, The Lancet.

[110]  J. Herbert,et al.  Fracture history and bone loss in patients with MS , 1998, Neurology.

[111]  L. Kurland The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada. , 1952, American journal of hygiene.

[112]  J. Peters,et al.  1,25‐Dihydroxyvitamin D3 Exerts Opposing Effects to IL‐4 on MHC Class‐II Antigen Expression, Accessory Activity, and Phagocytosis of Human Monocytes , 1993, Scandinavian journal of immunology.

[113]  Justin M. Nolan,et al.  Measurement of circulating vitamin D in man. , 1982, Clinica chimica acta; international journal of clinical chemistry.

[114]  J. Studd,et al.  A Pilot Study of the Effect upon Multiple Sclerosis of the Menopause, Hormone Replacement Therapy and the Menstrual Cycle , 1992, Journal of the Royal Society of Medicine.

[115]  S. Miller,et al.  The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. , 1994, Immunology today.